
In Vivo Contract Research Organization (CRO)
Description
Global In Vivo Contract Research Organization (CRO) Market to Reach US$8.0 Billion by 2030
The global market for In Vivo Contract Research Organization (CRO) estimated at US$5.3 Billion in the year 2024, is expected to reach US$8.0 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Smalll Molecules Modality, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Large Molecules Modality segment is estimated at 9.5% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 6.8% CAGR
The In Vivo Contract Research Organization (CRO) market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.2% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.
Global In Vivo Contract Research Organization (CRO) Market - Key Trends and Drivers Summarized
Why Is In Vivo Contract Research Organization (CRO) Crucial for Preclinical and Clinical Research?
In vivo Contract Research Organizations (CROs) are essential for conducting preclinical and clinical research in drug development, focusing on studies conducted within living organisms. These CROs provide services such as animal testing, pharmacokinetics, toxicology, and efficacy studies that are vital to the early stages of drug development. In vivo studies help assess how a drug behaves in a biological system, providing critical data on its safety, bioavailability, and potential therapeutic effects. Outsourcing these services to specialized CROs allows pharmaceutical and biotechnology companies to reduce costs, accelerate research timelines, and access expertise in regulatory compliance and animal testing protocols, making in vivo CROs indispensable in the development pipeline.
How Are Technological Advancements Shaping the In Vivo CRO Market?
Technological advancements in imaging, genomics, and data analytics are significantly enhancing the capabilities of in vivo CROs. Non-invasive imaging techniques, such as MRI, PET, and CT scans, have improved the ability to monitor drug effects and disease progression in real-time, providing more precise and detailed insights into drug efficacy and toxicity. Furthermore, advancements in genetic engineering and CRISPR technology have expanded the use of animal models, allowing for more targeted studies on specific diseases or genetic conditions. Data analytics and AI are also revolutionizing the in vivo CRO landscape by enabling faster and more accurate analysis of preclinical data, reducing the time it takes to make critical decisions in the drug development process.
How Do Market Segments Define the Growth of the In Vivo CRO Market?
Service types include toxicology, pharmacokinetics, pharmacodynamics, and efficacy studies, with toxicology services accounting for the largest market share due to regulatory requirements for drug safety testing. Therapeutic areas served by in vivo CROs include oncology, cardiovascular diseases, infectious diseases, and neurological disorders, with oncology leading the market as cancer remains a primary focus of drug development. End-users include pharmaceutical companies, biotechnology firms, and academic institutions, with pharmaceutical companies being the dominant segment due to their high demand for outsourced preclinical services. The market is also expanding in emerging regions, where CRO services are increasingly outsourced to countries with lower operational costs.
What Factors Are Driving the Growth in the In Vivo CRO Market?
The growth in the in vivo CRO market is driven by several factors, including increasing demand for preclinical and clinical research, the rising complexity of drug development, and the growing trend of outsourcing research activities. As pharmaceutical companies face mounting pressure to bring new drugs to market faster and more cost-effectively, they are turning to specialized CROs to handle in vivo studies, reducing the burden on internal resources. The growing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, is driving demand for in vivo studies to develop new therapeutics. Additionally, advancements in personalized medicine and biologics are increasing the complexity of preclinical research, making CROs a critical component of the drug development process.
SCOPE OF STUDY:The report analyzes the In Vivo Contract Research Organization (CRO) market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Modality (Smalll Molecules Modality, Large Molecules Modality); Model Type (Rodent-based Model, Non-Rodent based Model); Application (Oncology Application, CNS Application, Diabetes Application, Obesity Application, Pain Management Application, Other Applications)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 34 Featured) -
- American Preclinical Services, LLC.
- Charles River Laboratories
- Covance Inc.
- Evotec (US), Inc.
- ICON Plc
- inVentiv Health
- Parexel International
- Pharmaceutical Product Development, LLC (PPD)
- Quintiles
- Theorem Clinical research
- WuXi AppTec, Inc.
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Global Economic Update
- In Vivo Contract Research Organization (CRO) – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Increasing Outsourcing of R&D Activities Spurs Growth of In Vivo CRO Services
- Growing Focus on Drug Discovery and Development Expands Market Opportunity
- Rising Costs of In-House Research Drives Outsourcing to In Vivo CROs
- Technological Advancements in Imaging and Animal Models Strengthen Business Case for CRO Services
- Growth of Biotechnology and Pharmaceutical Sectors Fuels Demand for Preclinical Services
- Accelerating Drug Approval Timelines Drives Need for CRO Efficiency
- Increased Adoption of Personalized Medicine Propels Use of Specialized CROs
- Focus on Reducing Time-to-Market for New Drugs Sustains Demand for CRO Services
- Rising Number of Clinical Trials Generates Demand for In Vivo Testing
- Expansion of Biologics and Biosimilars Market Expands Opportunities for CROs
- Need for Compliance with International Standards Spurs Use of Reputable CROs
- Growth of Toxicology and Safety Testing Services Strengthens CRO Market
- Increasing Focus on Non-Animal Testing Methods Propels Innovation in CROs
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World In Vivo Contract Research Organization (CRO) Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for In Vivo Contract Research Organization (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Smalll Molecules Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Smalll Molecules Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Smalll Molecules Modality by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Large Molecules Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Large Molecules Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Large Molecules Modality by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Rodent-based Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Rodent-based Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Rodent-based Model by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Non-Rodent based Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Non-Rodent based Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Non-Rodent based Model by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for CNS Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for CNS Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for CNS Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Diabetes Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Obesity Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Pain Management Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for Pain Management Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for Pain Management Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 35: USA Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: USA Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: USA 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 38: USA Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: USA Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: USA 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 41: USA Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: USA Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: USA 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- CANADA
- TABLE 44: Canada Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Canada Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Canada 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 47: Canada Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Canada Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Canada 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 50: Canada Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Canada Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Canada 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- JAPAN
- In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 53: Japan Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Japan Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Japan 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 56: Japan Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Japan Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Japan 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 59: Japan Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Japan Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Japan 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- CHINA
- In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 62: China Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: China Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: China 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 65: China Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: China Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: China 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 68: China Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: China Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: China 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- EUROPE
- In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 71: Europe Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 72: Europe Historic Review for In Vivo Contract Research Organization (CRO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 74: Europe Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Europe Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 77: Europe Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Europe Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 80: Europe Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Europe Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- FRANCE
- In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 83: France Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: France Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: France 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 86: France Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: France Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: France 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 89: France Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: France Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: France 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- GERMANY
- In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 92: Germany Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Germany Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Germany 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 95: Germany Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Germany Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Germany 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 98: Germany Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Germany Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Germany 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- ITALY
- TABLE 101: Italy Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Italy Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Italy 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 104: Italy Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Italy Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Italy 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 107: Italy Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Italy Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Italy 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 110: UK Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: UK Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: UK 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 113: UK Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: UK Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: UK 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 116: UK Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: UK Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: UK 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: Rest of Europe Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: Rest of Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: Rest of Europe Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: Rest of Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Rest of Europe Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Rest of Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- In Vivo Contract Research Organization (CRO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Asia-Pacific Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: Asia-Pacific 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Asia-Pacific Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Asia-Pacific 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Asia-Pacific Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Asia-Pacific 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- REST OF WORLD
- TABLE 137: Rest of World Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Rest of World Historic Review for In Vivo Contract Research Organization (CRO) by Modality - Smalll Molecules Modality and Large Molecules Modality Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Rest of World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Modality - Percentage Breakdown of Value Revenues for Smalll Molecules Modality and Large Molecules Modality for the Years 2015, 2025 & 2030
- TABLE 140: Rest of World Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Rest of World Historic Review for In Vivo Contract Research Organization (CRO) by Model Type - Rodent-based Model and Non-Rodent based Model Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Rest of World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Model Type - Percentage Breakdown of Value Revenues for Rodent-based Model and Non-Rodent based Model for the Years 2015, 2025 & 2030
- TABLE 143: Rest of World Recent Past, Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Rest of World Historic Review for In Vivo Contract Research Organization (CRO) by Application - Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Rest of World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Application - Percentage Breakdown of Value Revenues for Other Applications, Oncology Application, CNS Application, Diabetes Application, Obesity Application and Pain Management Application for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates